REGENTIS BIOMATERIALS LIMITED (RGNT)

European surgeon training for GelrinC starts Q3 2026 in Milan, ahead of CE‑marked knee cartilage implant’s rollout and targeting a $3B U.S. repair market.

On the fundamentals, Regentis Biomaterials Ltd. is tiny. Total assets sit around $7.62M, with stockholders’ equity at about $4.74M and cash of $7.38M. That gives RGNT some runway, but retained earnings of roughly -$55.79M highlight a long history of losses.

Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3,

Regentis Biomaterials will launch European surgeon training for CE Mark–approved GelrinC in Q3 2026, building centers of excellence while targeting a $3B knee cartilage repair market.

Looking for the best stocks to buy? Follow the recommendations of top-performing analysts. Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Reg…